Seeking Alpha

Leonard Yaffe's  Instablog

Leonard Yaffe
Send Message
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
  • NASH Is The New Hep C 12 comments
    Jul 25, 2014 10:57 AM | about stocks: ICPT, GILD, GALT

    One of my focus areas has been hepatology, especially Hepatitis C and NASH. Regarding the latter, investors have focused primarily on Intercept Pharmaceuticals (ICPT, market cap. $4.8 billion), and to a lesser extent on Genfit (GNFT, market cap. $1.2 Billion). Gilead has been given very little credit for its drug, simtuzumab. On the more speculative investment side, Galectin Therapeutics (GALT, market cap. $300 million) is in phase 1 with its lead drug GR-MD-02, a galectin-3 inhibitor. This drug may be effective in treating more severe forms of NASH, which is extremely valuable from a pharmacoeconomic perspective. The company will be hosting a conference call Tuesday morning to discuss Phase 1 data. This company has excellent management and is targeting the appropriate patient population.

    Len

    Disclosure: The author is long ICPT, GILD, GALT, GNFTF.

    Stocks: ICPT, GILD, GALT
Back To Leonard Yaffe's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (12)
Track new comments
  • Joao Lourenco
    , contributor
    Comments (12) | Send Message
     
    maybe even more speculative (at least from market cap, float perspective), $CNAT? Phase 2 results expected 2nd half '14...
    25 Jul, 11:46 AM Reply Like
  • Leonard Yaffe
    , contributor
    Comments (83) | Send Message
     
    Author’s reply » I am not very excited about the prospects for their compound...Len
    25 Jul, 12:44 PM Reply Like
  • somedata1
    , contributor
    Comments (567) | Send Message
     
    What's NASH population? The potential could be huge with so many overweight people in the United States as well as in the world.
    25 Jul, 02:08 PM Reply Like
  • Leonard Yaffe
    , contributor
    Comments (83) | Send Message
     
    Author’s reply » In the US, NASH is estimated at 3-5% of the population. NAFL represents a much higher number, but would not require pharmacotherapy. As NASH progresses toward stage 4 fibrosis/cirrhosis, symptoms become more pronounced. A drug therapy would not represent a 12 week cure, as is currently the case with Hepatitis C; rather it would be taken over a longer period of time.
    25 Jul, 09:17 PM Reply Like
  • lucky54
    , contributor
    Comment (1) | Send Message
     
    My feeling is genfit will win the fight after keeping strategic view and calm (fast track, innocuity, secure..) compared ICPT who has stopped his phasis for declarating efficiency without treating security...you ll see...
    26 Jul, 12:15 PM Reply Like
  • Joao Lourenco
    , contributor
    Comments (12) | Send Message
     
    $GALT tomorrow any view on what's coming? Stock is about to take off it seems...
    28 Jul, 09:48 AM Reply Like
  • tedy77
    , contributor
    Comments (25) | Send Message
     
    oupps.

     

    Conatus of course.
    29 Jul, 11:29 AM Reply Like
  • Joao Lourenco
    , contributor
    Comments (12) | Send Message
     
    Somehow it took off...
    29 Jul, 11:41 AM Reply Like
  • DocHouse
    , contributor
    Comments (2) | Send Message
     
    Doc House

     

    I think GT505 (Genfit Sa) is safe, and will be a big actor
    10 Aug, 04:02 PM Reply Like
  • DocHouse
    , contributor
    Comments (2) | Send Message
     
    Gt 505 from GENFIT (french biotech) is safe, and will be a big actor. ICPT with OCA has some problems ( LDL higher with OCA)
    10 Aug, 04:02 PM Reply Like
  • tedy77
    , contributor
    Comments (25) | Send Message
     
    Yes me to.
    The Genfit product could be partnered early, before phase 2b data I think.
    If phase 2 of conatus is good, I think we will have a buyout by gilead.
    11 Aug, 01:35 AM Reply Like
  • Leonard Yaffe
    , contributor
    Comments (83) | Send Message
     
    Author’s reply » ICPT just reported an update on the FLINT trial results, and there was slight, statistically significant improvement in fibrosis vs. placebo, and the lipid profile appeared much better than earlier suggested. This round goes to the bulls. Len
    11 Aug, 05:30 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.